trending Market Intelligence /marketintelligence/en/news-insights/trending/YkUSE2YnXolrVIhXXPKMcQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

DaVita settles unlawful billing case with US Justice Department for $63.7M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

DaVita settles unlawful billing case with US Justice Department for $63.7M

The U.S. Justice Department said DaVita Inc. agreed to pay $63.7 million to resolve claims relating to improper billing practices and unlawful financial inducements to federal healthcare program beneficiaries.

DaVita unit DaVita Rx LLC was being investigated under the False Claims Act for alleged improper billing practices, according to the U.S. Attorney's Office for the Northern District of Texas.

The settlement resolves allegations that DaVita Rx billed federal healthcare programs for prescription medications that were never shipped; shipped but later returned; and did not comply with requirements for documentation of proof of delivery, refill requests, or patient consent.

In addition, the settlement resolves claims that DaVita paid financial inducements to federal healthcare program beneficiaries in violation of the Anti-Kickback Statute.

These allegations relating to improper billing and unlawful financial inducements were the subject of self-disclosures by DaVita Rx and a subsequently filed whistleblower lawsuit. The lawsuit was filed by two former DaVita Rx employees under the whistleblower provisions of the False Claims Act.

DaVita Rx repaid about $22.2 million to federal healthcare programs following its self-disclosure and will pay an additional $38.3 million to the U.S. as part of the settlement agreement. In addition, $3.2 million has been allocated to cover Medicaid program claims by states that elect to participate in the settlement.

DaVita said it takes "full ownership" and will continue to embrace transparency and rigorous compliance. It added that its team discovered and self-disclosed these issues to the federal government in 2015 and 2016 and cooperated with the government in resolving them.

U.S. Attorney Erin Nealy Cox for the Northern District of Texas said, "the U.S. Attorney's Office has and will continue to work cooperatively with providers that bring such issues to light to redress the losses the federal healthcare system has incurred."